Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Alopecia areata involves immune system changes, especially in severe cases, with potential new treatment targets identified.

People with atopic dermatitis have more CD4+ T cells that respond to a certain bacterial lipid, which may play a role in the skin condition's inflammation.

Regulatory T cells play a key role in different types of hair loss.

Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.

Giving immune serum from vaccinated mice to mice without T cells prevents infection and tumor growth.

BST2 is highly expressed in certain immune cells in alopecia areata, suggesting a role in the disease.

Blocking LFA-1 prevents hair loss in mice.

Certain genes may be linked to autoimmune conditions in people with alopecia areata.

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

Regular monitoring of autoantibodies in ANA-positive patients with hair loss helps detect and treat lupus early.

Targeted cytokine treatments may help with alopecia areata, but more research is needed.

Alopecia areata is caused by the immune system attacking hair follicles.

IL-15 is key for T cell function and could help improve treatments for immune-related diseases.

IL-27 can prevent hair loss in alopecia areata.

Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.

The study concluded that there is no significant link between thyroid autoimmunity and alopecia areata.

Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Alopecia areata is an autoimmune disease that targets hair follicles.

Patients with thyroid disorders show different symptoms and antibody levels.

The study identified key immune cell differences between mild and severe alopecia areata.

Higher PD-1 levels mean fewer CD8+ T cells in alopecia areata hair follicles.

Targeting CXCL10 may help treat alopecia areata.

Dual TCR Treg cells are common in mouse tissues and vary by location.

Atopy and altered T cell functions contribute to Alopecia Areata.

Psoriasis involves an imbalance between certain immune cells, and targeting these could help restore skin health.